

# 2019 Employer Oncology Management & Benefit Design: Research Preview

Gallagher Research & Insights | Fall 2019



**Gallagher**

Insurance | Risk Management | Consulting

# Table of Contents

- » Methodology & Panel Overview
- » Executive Summary
- » Employer Oncology Segmentation
- » Cancer as a Workforce Issue
- » Decision Making in Oncology Management
- » Oncology Benefit Design & Program Offerings
- » Value-Driven Approaches to Oncology Management
- » Appendix

# List of Figures

Figure 1: Description of Oncology Segmentation Quadrants

Figure 2: Segmentation Characterization

Figure 3: Components of Segmentation Y-Axis

Figure 4: Components of Segmentation X-Axis

Figure 5: Segmentation Placement & Percentage of Employer Research Participants

Figure 6: Description of Upper Right Quadrant

Figure 7: Segmentation Distribution from 2017 to 2019

Figure 8: Employer Focus on Cancer

Figure 9: Cancer as a Top 5 Workforce Issue

Figure 10: Top Cancer Types Driving Costs to Organization

Figure 11: Cancer Types for which Specific Prevention and/or Support Services are Offered

Figure 12: Impact of Factors Driving Increasing Costs of Cancer Care

Figure 13: Employer Familiarity with Immunotherapies

Figure 14: Expected Impact of Biosimilars on Total Specialty Drug Spend

Figure 15: Employer Perspectives on Managing Cancer Benefit Design

Figure 16: Employer Perspectives on Managing the Quality of Cancer Care

Figure 17: Top Factors Influencing Employer Decisions Around Oncology Management & Benefit Design

Figure 18: Stakeholder Influence on Oncology Benefit Management Decisions

Figure 19: Approach to External Stakeholder (Health Plan, PBM, Benefits Advisors, Oncology/Condition Experts, NCCN, etc.)  
Recommendations

Figure 20: Sources of Information on Cancer Treatment & Innovations

Figure 21: Interest in Information to Evaluate Coverage of New Cancer Therapies

# List of Figures *(cont.)*

Figure 22: Employer Interest in Cancer Treatment & Innovation Information from Biopharma Manufacturers

Figure 23: Employer Treatment of Cancer-Specific Medical and Pharmacy Benefits

Figure 24: Cancer Management Benefit Design & Programs

Figure 25: Employers' Expected Change in Proportion of Future Cancer Spend (3-5 Years) Through the Pharmacy Benefit

Figure 26: Success of Cancer Management Benefit Design & Programs

Figure 27: Value-Based Approaches to Cancer Management

Figure 28: Use of Financial Incentives vs Mandates for Oncology Management Programs & Initiatives

Figure 29: Likelihood Employer would Cover New Diagnostic Tests that Could Identify Patients Most Likely to Respond to a Treatment

Figure 30: Success of Value-Based Approaches to Cancer Management

Figure 31: Top Barriers to Implementing a Direct Contract with Providers for Cancer Care

Figure 32: Familiarity with Value Frameworks Focused on Treatment Quality and Cost

Figure 33: Received Information on Value Frameworks

Figure 34: Rate of Medical and Rx Cancer Cost Increase When Employers Would Take Action

## **Appendix**

Figure A1: Size of Employee Population

Figure A2: Industry Breakdown

Figure A3: Segmentation Placement by Plot Point

Figure A4: Employer Research Participants

# Methodology & Panel Overview

## Research Objective

*The Employer Oncology Management & Benefit Design Report is designed to help biopharma understand employers' current and emerging perspectives, attitudes and strategies related pertaining to cancer care and related healthcare programs.*

*In so doing, this report aims to inform biopharma decisions regarding whether and how to engage with employer-purchasers for the purpose of improving access to cancer treatments.*



## 81 EMPLOYER SURVEYS

67% | Director/VP of Benefits

26% | Benefits Manager

6% | Medical Director

1% | Benefits Analyst



## 10 STAKEHOLDER INTERVIEWS

9 Employers | 1 Coalition




## 4M COVERED LIVES

Average Employer Size: 34K U.S. EEs

# Figure 5: Segmentation Placement & Percentage of Employer Research Participants

*\*Full list of corresponding employer names is available to report subscribers.*




Note: A single number may represent multiple employers.

n=81 Employers


# When do employers stop managing cancer with a light touch? By 2021, 60% of employers are taking significant steps to manage cancer

**Figure 8: Employer Focus on Cancer**



# The impact of factors surrounding waste and variability in oncology care are recognized cost drivers for employers

**Figure 12: Impact of Factors Driving Increasing Costs of Cancer Care\***  
(percent rating high impact)




*\*Only select bars are featured as part of the research preview—Full data available to report subscribers.*

n=81 Employers



# Health plans and PBMs play the largest role in providing cancer treatment information, but employers turn to multiple sources to keep informed

**Figure 20: Sources of Information on Cancer Treatment & Innovations\***  
(select all that apply)




*\*Only select bars are featured as part of the research preview—Full data available to report subscribers.*

n=81 Employers

# When evaluating coverage of new cancer therapies, information on price is just one of many areas of high interest to employers

**Figure 21: Top 5 Areas of Interest in Information to Evaluate Coverage of New Cancer Therapies\***  
*(percent highly interested)*



*\*Only select bars are featured as part of the research preview—Full data available to report subscribers.*

n=81 Employers

*For additional details on the report content and pricing, please contact us below:*

**Scott Thompson**

Area President | [Scott\\_Thompson@ajg.com](mailto:Scott_Thompson@ajg.com)

**Stephanie Bauman**

Senior Vice President | [Stephanie\\_Bauman@ajg.com](mailto:Stephanie_Bauman@ajg.com)

12444 Powerscourt Drive, Suite 250,  
St. Louis, MO 63131



**Gallagher**

Insurance | Risk Management | Consulting